View in EDS

Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.

Saved in:
Bibliographic Details
Title: Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.
Authors: Chen EY; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Electronic address: cheem@ohsu.edu., Nabavizadeh N; Department of Radiation Medicine, Oregon Health & Science University, Portland, OR., Kendsersky ND; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Lessenich C; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Herzig DO; Division of Gastrointestinal and General Surgery, Oregon Health & Science University, Portland, OR., Korngold E; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR., Goodyear SM; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Kennecke HF; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Kardosh A; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Tsikitis VL; Division of Gastrointestinal and General Surgery, Oregon Health & Science University, Portland, OR., Lu KC; Division of Gastrointestinal and General Surgery, Oregon Health & Science University, Portland, OR., Fang S; Division of Gastrointestinal and General Surgery, Oregon Health & Science University, Portland, OR., Wong M; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Pegna GJ; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Rocha FG; Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Mayo SC; Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Brinkerhoff B; Department of Pathology, Oregon Health & Science University, Portland, OR., Taber E; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Rajagopalan B; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Park BS; Biostatistics Shared Resource, OHSU Knight Cancer Institute, OHSU School of Medicine, Portland, OR., Thomas CR Jr; Department of Radiation Oncology & Applied Sciences, Geisel School of Medicine, Hanover, NH., Lopez CD; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Electronic address: lopezc@ohsu.edu.
Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2026 Jun; Vol. 25 (2), pp. 249-257.e2. Date of Electronic Publication: 2026 Feb 04.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0674
DOI:10.1016/j.clcc.2026.02.001